Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Cancer

Step counting can help predict outcomes for patients undergoing lung cancer treatment

Research has suggested that step counters can help predict outcomes for patients receiving lung cancer therapy by acting as an indicator of how physically active they are during their treatment period.

Woman undergoing radiotherapy

Source: Shutterstock.com

Researchers examined whether step counters could help predict outcomes for patients with non-small cell lung cancer, by using them as an indicator of activity levels before undergoing chemoradiation therapy

Measuring patients’ step counts before they receive lung cancer treatment could help predict outcomes, research published in the International Journal of Radiation Oncology, Biology, Physics (15 November 2019) has suggested[1].

Researchers from the Albert Einstein College of Medicine, New York, recorded the activity of 50 patients with locally advanced, non-small cell lung cancer who wore step counters before undergoing chemoradiation therapy. Patients were categorised as inactive (n=18)] or moderately or highly active (n=32), based on the number of steps they took each day, adjusted for their age.

Inactive patients were more likely to be admitted to hospital during their radiotherapy course or to experience treatment delays, and were at increased risk for disease progression or death.

Half of those in the inactive group were admitted to hospital during treatment, compared with 9% of those who were moderately or highly active (odds ratio 9.7; P=0.003). The median duration for progression-free survival for inactive patients was 5.3 months, compared with 18.3 months for active patients.

“I consider step counts to be a new vital sign for cancer treatment,” said Nitin Ohri, a radiation oncologist at Montefiore Medical Center in New York and lead investigator in the study.

“Having an objective indicator of patients’ functional status could be critical in identifying who needs extra care during treatment.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20207678

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.